(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 January 2013 (10.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/006486 A9

(51) International Patent Classification:
C07K 19/00 (2006.01) *A61K 38/18* (2006.01)
C12N 15/62 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/US2012/045087

(22) International Filing Date:
29 June 2012 (29.06.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/504,128 1 July 2011 (01.07.2011) US
61/515,126 4 August 2011 (04.08.2011) US

(71) Applicant *(for all designated States except US)*: **NGM BIOPHARMACEUTICALS, INC.** [US/US]; 630 Gateway Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LING, Lei** [US/US]; 411 Nantucket Street, Foster City, CA 94404 (US). **LINDHOUT, Darrin, A.** [CA/US]; 1533 Miramonte Avenue, Mountain View, CA 94040 (US).

(74) Agent: **WEISSER, Tamera, M.**; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(48) Date of publication of this corrected version:
15 August 2013

[Continued on next page]

(54) Title: COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES




FIG. 3A

(***P<0.001 vs. Saline)

(57) Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

WO 2013/006486 A9

(15) Information about Correction:
see Notice of 15 August 2013